Syntara Limited (ASX:SNT)

Market Cap	53.87M
Revenue (ttm)	7.30M +26.6%
Net Income	-7.92M
EPS	-0.01
Shares Out	1.63B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	629,754
Average Volume	1,177,778
Open	0.0340
Previous Close	0.0330
Day's Range	0.0320 - 0.0340
52-Week Range	0.0230 - 0.0950
Beta	0.28
RSI	48.75
Earnings Date	Feb 24, 2026

About Syntara

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 21
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SNT

Financial Performance

In 2025, Syntara's revenue was 7.30 million, an increase of 26.61% compared to the previous year's 5.76 million. Losses were -7.92 million, -47.70% less than in 2024.